Travere Therapeutics (TVTX) Other Non Operating Income (2013 - 2026)
Travere Therapeutics (TVTX) posted Other Non Operating Income of -$91000.0 for Q1 2026, up 87.53% on a QoQ basis from -$730000.0 in Q4 2025, and down 116.58% year-over-year from $549000.0 in Q1 2025.
Travere Therapeutics (TVTX) Other Non Operating Income (2013 - 2026) Analysis & Trends
Travere Therapeutics' Other Non Operating Income history runs 14 years deep, the most recent figure standing at -$91000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 116.58% year-over-year to -$91000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$860000.0 (down 4958.82% YoY) and the FY2025 annual result came in at -$219000.0, up 33.23% from the prior year.
- Other Non Operating Income was -$91000.0 for Q1 2026 at Travere Therapeutics, up from -$730000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.4 million in Q4 2024 and bottomed at -$3.5 million in Q2 2024.
- A 5-year average of -$54933.3 and a median of $87000.0 in 2023 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 1464.29% in 2024, while the deepest fall reached 1638.81% in 2024.
- Travere Therapeutics' Other Non Operating Income stood at -$586000.0 in 2022, then soared by 126.28% to $154000.0 in 2023, then jumped by 1464.29% to $2.4 million in 2024, then plunged by 130.3% to -$730000.0 in 2025, then surged by 87.53% to -$91000.0 in 2026.
- Business Quant data shows TVTX's Other Non Operating Income at -$91000.0 in Q1 2026, -$730000.0 in Q4 2025, and $487000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 5.25 Bn | 5.25 Bn | 125.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91,000.00 |
| Dec 31, 2025 | -730,000.00 |
| Sep 30, 2025 | 487,000.00 |
| Jun 30, 2025 | -526,000.00 |
| Mar 31, 2025 | 549,000.00 |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 520,000.00 |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | 238,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 335,000.00 |
| Jun 30, 2023 | -201,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Sep 30, 2022 | -586,000.00 |
| Mar 31, 2022 | 26,000.00 |
| Dec 31, 2021 | -860,000.00 |
| Sep 30, 2021 | 654,000.00 |
| Jun 30, 2021 | 216,000.00 |
| Mar 31, 2021 | -1.09 Mn |
| Dec 31, 2020 | 620,000.00 |